Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stomach-Draining Device Makes Play For Obesity Surgery Patients

This article was originally published in The Gray Sheet

Executive Summary

Approved as a long-term treatment option for obese patients with a body-mass index of 35 to 55, Aspire Bariatrics is positioning its AspireAssist device as a less-invasive alternative to bariatric surgery in the population of morbidly obese individuals who are most often recommended for a procedure. The system includes an endoscopically implanted tube and a port used by the patient to drain contents of the stomach and reduce calories absorbed.

You may also be interested in...



ReShape Dual Balloon Enters U.S. Market, Headlining Week Of Obesity Device News

It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and, on the same day, Aspire Bariatrics reached a key milestone with the PMA submission for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.

FDA Proposes Sliding-Scale Paradigm For Obesity Device Trials

Higher-risk devices, based on feasibility trial adverse event rates, would be matched to steeper effectiveness targets in pivotal studies for weight-loss under a plan outlined by the agency.

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Topics

Related Companies

UsernamePublicRestriction

Register

MT034869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel